FR2922209B1 - 5,6-DIARYLES PYRIDINES SUBSTITUES EN POSITION 2 et 3, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE. - Google Patents

5,6-DIARYLES PYRIDINES SUBSTITUES EN POSITION 2 et 3, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE.

Info

Publication number
FR2922209B1
FR2922209B1 FR0707186A FR0707186A FR2922209B1 FR 2922209 B1 FR2922209 B1 FR 2922209B1 FR 0707186 A FR0707186 A FR 0707186A FR 0707186 A FR0707186 A FR 0707186A FR 2922209 B1 FR2922209 B1 FR 2922209B1
Authority
FR
France
Prior art keywords
diaryles
therapeutics
preparation
pyridines substituted
pyridines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0707186A
Other languages
English (en)
Other versions
FR2922209A1 (fr
Inventor
Lionel Barre
Christian Congy
Philippe Pointeau
Carmona Murielle Rinaldi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39387099&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2922209(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Priority to FR0707186A priority Critical patent/FR2922209B1/fr
Priority to PA20088798201A priority patent/PA8798201A1/es
Priority to TW097139016A priority patent/TW200922567A/zh
Priority to PCT/FR2008/001421 priority patent/WO2009087285A1/fr
Priority to EP08869799A priority patent/EP2209768A1/fr
Priority to UY31387A priority patent/UY31387A1/es
Priority to CA2702012A priority patent/CA2702012A1/fr
Priority to PE2008001755A priority patent/PE20091034A1/es
Priority to JP2010528446A priority patent/JP5465179B2/ja
Priority to CL2008003027A priority patent/CL2008003027A1/es
Priority to MX2010003983A priority patent/MX2010003983A/es
Priority to CN200880115604A priority patent/CN101855208A/zh
Priority to AU2008346293A priority patent/AU2008346293A1/en
Priority to BRPI0818061 priority patent/BRPI0818061A2/pt
Priority to ARP080104435A priority patent/AR068778A1/es
Priority to KR1020107007838A priority patent/KR20100065377A/ko
Priority to EA201070460A priority patent/EA201070460A1/ru
Publication of FR2922209A1 publication Critical patent/FR2922209A1/fr
Priority to US12/755,883 priority patent/US8362045B2/en
Priority to IL205016A priority patent/IL205016A0/en
Priority to MA32824A priority patent/MA31839B1/fr
Publication of FR2922209B1 publication Critical patent/FR2922209B1/fr
Application granted granted Critical
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR0707186A 2007-10-12 2007-10-12 5,6-DIARYLES PYRIDINES SUBSTITUES EN POSITION 2 et 3, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE. Expired - Fee Related FR2922209B1 (fr)

Priority Applications (20)

Application Number Priority Date Filing Date Title
FR0707186A FR2922209B1 (fr) 2007-10-12 2007-10-12 5,6-DIARYLES PYRIDINES SUBSTITUES EN POSITION 2 et 3, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE.
PA20088798201A PA8798201A1 (es) 2007-10-12 2008-10-09 5,6-diarilpiridinas sustituidas en posición 2 y 3,su preparación y su aplicación terapéutica."
TW097139016A TW200922567A (en) 2007-10-12 2008-10-09 5,6-diarylpyridines substituted in positions 2 and 3, preparation and therapeutic application thereof
MX2010003983A MX2010003983A (es) 2007-10-12 2008-10-10 5,6-diarilpiridinas sustituidas en la posicion 2 y 3, su preparacion y su uso terapeutico.
ARP080104435A AR068778A1 (es) 2007-10-12 2008-10-10 5, 6 - diarilpiridinas sustituidas en posicion 2 y 3, intermediarios utilizados en su preparacion, una composicion farmaceutica que las comprende y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por los receptores de cannabinoides cb1.
UY31387A UY31387A1 (es) 2007-10-12 2008-10-10 5,6-diarilpiridinas sustituidas en posicion 2 y 3, su preparacion y su aplicacion terapéutica
CA2702012A CA2702012A1 (fr) 2007-10-12 2008-10-10 5,6-diaryles pyridines substitues en position 2 et 3, leur preparation et leur application en therapeutique
PE2008001755A PE20091034A1 (es) 2007-10-12 2008-10-10 5,6-diarilpiridinas sustituidas en posicion 2 y 3 con actividad sobre los receptores cannabinoides
JP2010528446A JP5465179B2 (ja) 2007-10-12 2008-10-10 ２−および３−位において置換されている５，６−ジアリールピリジン、これらの調製およびこれらの治療上の使用
CL2008003027A CL2008003027A1 (es) 2007-10-12 2008-10-10 Compuestos derivados de 5,6-diaril piridinas sustituidas en posiciones 2 y 3; compuestos intermediarios y su uso; composicion farmaceutica; y uso para tratar y/o prevenir trastornos psiaquiatricos, metabolicos, inflamatorios, para la prevencion del dolor, entre otras enfermedades.
PCT/FR2008/001421 WO2009087285A1 (fr) 2007-10-12 2008-10-10 5,6-diaryles pyridines substitues en position 2 et 3, leur preparation et leur application en therapeutique
CN200880115604A CN101855208A (zh) 2007-10-12 2008-10-10 在2-和3-位被取代的5,6-二芳基吡啶、其制备和其治疗应用
AU2008346293A AU2008346293A1 (en) 2007-10-12 2008-10-10 5,6-diaryl pyridines substituted in the 2- and 3-position, preparation thereof and therapeutic use thereof
BRPI0818061 BRPI0818061A2 (pt) 2007-10-12 2008-10-10 5,6-diaril piridinas substituídas em posição 2 e 3, preparação das mesmas e aplicação das mesmas em terapia.
EP08869799A EP2209768A1 (fr) 2007-10-12 2008-10-10 5,6-diaryles pyridines substitues en position 2 et 3, leur preparation et leur application en therapeutique
KR1020107007838A KR20100065377A (ko) 2007-10-12 2008-10-10 ２- 및 ３-위치에서 치환된 ５,６-디아릴 피리딘, 그의 제법, 및 그의 치료학적 용도
EA201070460A EA201070460A1 (ru) 2007-10-12 2008-10-10 5,6-диарилпиридины, замещенные в положении 2 и 3, способ их получения и применение их в терапии
US12/755,883 US8362045B2 (en) 2007-10-12 2010-04-07 5,6-diaryl pyridines substituted in the 2- and 3-position, preparation thereof and therapeutic use thereof
IL205016A IL205016A0 (en) 2007-10-12 2010-04-11 5,6-diaryl pyridines substituted in the 2- and 3-position, preparation thereof and therapeutic use thereof
MA32824A MA31839B1 (fr) 2007-10-12 2010-05-10 5,6-diaryles pyridines substitues en position 2 et 3, leur preparation et leur application en therapeutique

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0707186A FR2922209B1 (fr) 2007-10-12 2007-10-12 5,6-DIARYLES PYRIDINES SUBSTITUES EN POSITION 2 et 3, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE.

Publications (2)

Publication Number Publication Date
FR2922209A1 FR2922209A1 (fr) 2009-04-17
FR2922209B1 true FR2922209B1 (fr) 2010-06-11

Family

ID=39387099

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0707186A Expired - Fee Related FR2922209B1 (fr) 2007-10-12 2007-10-12 5,6-DIARYLES PYRIDINES SUBSTITUES EN POSITION 2 et 3, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE.

Country Status (20)

Country Link
US (1) US8362045B2 (fr)
EP (1) EP2209768A1 (fr)
JP (1) JP5465179B2 (fr)
KR (1) KR20100065377A (fr)
CN (1) CN101855208A (fr)
AR (1) AR068778A1 (fr)
AU (1) AU2008346293A1 (fr)
BR (1) BRPI0818061A2 (fr)
CA (1) CA2702012A1 (fr)
CL (1) CL2008003027A1 (fr)
EA (1) EA201070460A1 (fr)
FR (1) FR2922209B1 (fr)
IL (1) IL205016A0 (fr)
MA (1) MA31839B1 (fr)
MX (1) MX2010003983A (fr)
PA (1) PA8798201A1 (fr)
PE (1) PE20091034A1 (fr)
TW (1) TW200922567A (fr)
UY (1) UY31387A1 (fr)
WO (1) WO2009087285A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201103419D0 (fr) 2011-02-28 2011-04-13 Univ Aberdeen
WO2013075083A1 (fr) 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées
WO2013075084A1 (fr) 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées
AU2013216721B2 (en) 2012-02-10 2017-09-28 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9745305B2 (en) 2013-03-15 2017-08-29 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP3033334A1 (fr) 2013-08-15 2016-06-22 Constellation Pharmaceuticals, Inc. Dérivés d'indole utilisés en tant que modulateurs d'enzymes de modification du méthyle, compositions et utilisations associées
US10577350B2 (en) 2015-08-28 2020-03-03 Constellation Pharmaceuticals, Inc. Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide
EP3529242A1 (fr) 2016-10-19 2019-08-28 Constellation Pharmaceuticals, Inc. Synthèse d'inhibiteurs d'ezh2
EP3575286B1 (fr) 2017-01-26 2022-05-11 Mitsui Chemicals Agro, Inc. Composé de pyridone et bactéricide à usage agricole et horticole utilisant celui-ci en tant que principe actif

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686470A (en) * 1995-02-10 1997-11-11 Weier; Richard M. 2, 3-substituted pyridines for the treatment of inflammation
WO2002055502A1 (fr) 2001-01-02 2002-07-18 Fujisawa Pharmaceutical Co., Ltd. Derives de pyridine utiles en tant qu'inhibiteurs de cyclo-oxygenase
US7271266B2 (en) * 2002-03-28 2007-09-18 Merck & Co., Inc. Substituted 2,3-diphenyl pyridines
GB0314057D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
FR2876691B1 (fr) * 2004-10-18 2006-12-29 Sanofi Aventis Sa Derives de pyridine, leur preparation, leur application en therapeutique
CA2606288A1 (fr) 2005-04-18 2006-10-26 Neurogen Corporation Antagonistes cb1 heteroaryle substitue

Also Published As

Publication number Publication date
AR068778A1 (es) 2009-12-02
MX2010003983A (es) 2010-05-27
PE20091034A1 (es) 2009-08-19
WO2009087285A1 (fr) 2009-07-16
US8362045B2 (en) 2013-01-29
TW200922567A (en) 2009-06-01
CL2008003027A1 (es) 2009-10-16
AU2008346293A1 (en) 2009-07-16
CA2702012A1 (fr) 2009-07-16
IL205016A0 (en) 2010-11-30
MA31839B1 (fr) 2010-11-01
PA8798201A1 (es) 2009-05-15
CN101855208A (zh) 2010-10-06
BRPI0818061A2 (pt) 2015-03-31
EA201070460A1 (ru) 2010-10-29
JP5465179B2 (ja) 2014-04-09
KR20100065377A (ko) 2010-06-16
FR2922209A1 (fr) 2009-04-17
JP2011500543A (ja) 2011-01-06
WO2009087285A4 (fr) 2009-09-24
EP2209768A1 (fr) 2010-07-28
US20100256202A1 (en) 2010-10-07
UY31387A1 (es) 2009-05-29

Similar Documents

Publication Publication Date Title
FR2922209B1 (fr) 5,6-DIARYLES PYRIDINES SUBSTITUES EN POSITION 2 et 3, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE.
FR2918061B1 (fr) Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique.
FR2915199B1 (fr) Derives de triazolopyridine-carboxamides et triazolopyrimidine-carboxamides, leur preparation et leur application en therapeutique.
FR2915198B1 (fr) Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique.
FR2910473B1 (fr) Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2- carboxamides, leur preparation et leur application en therapeutique.
BRPI0808098A2 (pt) 4-aril-1,4-di-hidro-1,6-naftiridinamidas substituídas e seu uso
FR2885364B1 (fr) Derives d'alkyl-, alkenyl-et alkynylcarbamates, leur preparation et leur application en therapeutique
FR2915197B1 (fr) Derives de triazolopyridine-carboxamides, leur preparation et leur application therapeutique.
BRPI0812766A2 (pt) 4-cloro-4-alcóxi-1,1,1-triflúor-2-butanonas, preparação das mesmas e uso das mesmas no preparo de 4-alcóxi-1,1,1-triflúor-3-buten-2-onas
FR2909090B1 (fr) Derives de 2,5-dihydro-3h-pyrazolo[4,3-c]pyridazin-3-one substitues,leur preparation et leur application en therapeutique.
FR2917412B1 (fr) Derives de 7-alkynyl, 1,8-naphthyridones, leur preparation et leur application en therapeutique
ZA200900835B (en) 5,6-bisaryl-2-pyridine-carboxamide derivatives, preparation and application thereof in therapeutics as urotensin II receptor antagonists
FR2866340B1 (fr) Derives d'oxazole, leur preparation et leur utilisation en therapeutique.
GB2452696B (en) 3-(2',2'-dimethylpropanoylamino)-tetrahydropyridin-2-one and its use in pharmaceutical compositions
FR2917413B1 (fr) Derives de 7-alkynyl-1,8-naphthyridones, leur preparation et leur application en therapeutique
FR2873118B1 (fr) Derives de pyrido-pyrimidine, leur application en therapeutique
FR2908766B1 (fr) Derives de pyrrole,leur preparation et leur utilisation en therapeutique.
FR2930249B1 (fr) Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique.
FR2892416B1 (fr) Derives de 6-heteroarylpyridoindolone, leur preparation et leur application en therapeutique
FR2887548B1 (fr) Derives de 4,5-diarylpyrrole, leur preparation et leur application en therapeutique
MA28847B1 (fr) Derives de pyrrole, leur preparation et leur utilisation en therapeutique
FR2940284B1 (fr) Derives de 6-cycloamino-2,3-di-pyridinyl-imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique
FR2925901B1 (fr) DERIVES DE N-HETEROCYCLIQUE-IMIDAZO°1,2-a!PYRIDINE-2- CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
FR2912404B1 (fr) Derives d'azabicycloalkane,leur preparation et leur application en therapeutique.
FR2934594B1 (fr) Derives de thiophene-2-carboxamide, leur preparation et leur application en therapeutique.

Legal Events

Date Code Title Description
RN Application for restoration
FC Decision of inpi director general to approve request for restoration
PLFP Fee payment

Year of fee payment: 9

ST Notification of lapse

Effective date: 20170630